Effectiveness of Pneumococcal Vaccine in HIV-Infected Adults in Brazil
Author Information
Author(s): Maria Amelia SM Veras, Wayne TA Enanoria, Euclides A Castilho, Arthur L Reingold
Primary Institution: University of California, Berkeley
Hypothesis
What is the effectiveness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal infection among HIV-infected adults in Brazil?
Conclusion
The study found no statistically significant protective effect of the pneumococcal vaccine against invasive pneumococcal infection among HIV-infected adults in Brazil.
Supporting Evidence
- The vaccine effectiveness was estimated at 18%, which is low.
- The study included a total of 321 participants, with 79 cases and 242 controls.
Takeaway
The pneumococcal vaccine might not help people with HIV in Brazil as much as we hoped.
Methodology
A case-control study with 79 cases and 242 controls matched on CD4+ cell count and health care setting.
Potential Biases
Potential biases may arise from the observational nature of the study and matching criteria.
Limitations
The study could not include all patients with invasive pneumococcal disease due to various reasons, including consent issues.
Participant Demographics
HIV-infected adults over 18 years old in São Paulo, Brazil.
Statistical Information
Confidence Interval
95% CI: <0 to 62%
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website